. The majority
of participants that did not respond to the treatment had received chemotherapy in the metastatic
castration-resistant prostate cancer (mCR P C) stage, were part of the lowest dose cohort (cohort 1)
and had some of the highest PSA levels at study entry.
Thats makes sense. They had the lowest dose but were already at the cancer stops responding to hormone treatment, and it is found in other parts of the body.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.24 |
Change
0.010(0.45%) |
Mkt cap ! $719.8M | |||
| Open | High | Low | Value | Volume |
| $2.30 | $2.37 | $2.21 | $6.293M | 2.748M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5025 | $2.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.26 | 17072 | 2 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| CU6 (ASX) Chart |